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Nonalcoholic fatty liver disease (NAFLD) is now the most frequent chronic liver disease in Western societies,
affecting one in four adults in the USA, and is strongly associated with hepatic insulin resistance, a major risk
factor in the pathogenesis of type 2 diabetes. Although the cellular mechanisms underlying this relationship
are unknown, hepatic accumulation of diacylglycerol (DAG) in both animals and humans has been linked
to hepatic insulin resistance. In this Perspective, we discuss the role of DAG activation of protein kinase
Cε as the mechanism responsible for NAFLD-associated hepatic insulin resistance seen in obesity, type 2
diabetes, and lipodystrophy.Introduction
Nonalcoholic fatty liver disease (NAFLD), now the most common
chronic liver disease in the world with a prevalence of about
20%–30% in Western countries, is a major risk factor in the
development of type 2 diabetes, most likely due to its strong
association with hepatic insulin resistance (Angulo, 2002; Fab-
brini et al., 2010; Shulman, 2000). In this Perspective, we briefly
review recent studies in both rodents and humans supporting
diacylglycerol-activation of protein kinase Cε (PKCε) as a key
pathway responsible for causing NAFLD-associated hepatic
insulin resistance.
Diacylglycerol-Induced Hepatic Insulin Resistance
Mice with targeted overexpression of lipoprotein lipase (LPL)
in the liver develop liver-specific steatosis associated with
liver-specific hepatic insulin resistance, demonstrating that
hepatic insulin resistance can occur independently of changes
in circulating adipocytokines (tumor necrosis factor-a [TNF-a],
interleukin-6 [IL-6], resistin, adiponectin, retinol binding
protein-4 [RBP-4], etc.) (Kim et al., 2001a). Hepatic steatosis
and hepatic insulin resistance can also be induced in mice and
rats through 3 days of high-fat feeding before the development
of obesity and increases in circulating adipocytokines (Samuel
et al., 2004). In this model of hepatic insulin resistance, hepatic
steatosis was associated with decreased insulin-stimulated
insulin receptor substrate-2 (IRS-2) tyrosine phosphorylation
by the insulin receptor kinase, leading to the inability of insulin
to activate hepatic glycogen synthesis and suppress hepatic
glucose production. In this case, hepatic insulin resistance was
associated with an increase in hepatic diacylglycerol (DAG)
content. The link between hepatic DAG accumulation and
hepatic insulin resistance could be attributed to activation of
PKCε, which was the predominant PKC isoform activated in liver
following fat feeding (Samuel et al., 2004). PKCε is a member of
the PKC family, which is composed of three different groups:
conventional (a, bI, bII, and g), novel (d, ε, h, and q) and atypical
(z and l) (Newton, 2003). PKCε is a novel PKC isoform with574 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.a much greater affinity for DAG than the conventional PKC
isoforms (Dries et al., 2007), which are activated when calcium
binds to the C2 domain, increasing the affinity of the C1 domain
for DAG and, subsequently, leading to the removal of a pseudo-
substrate from the catalytic domain. Phorbol esters have been
shown to activate PKCs and impair activation of the insulin
receptor in vitro (Pillay et al., 1990; Takayama et al., 1988).
DAGs have different stereoisomers, and it has been shown
that activation of PKC can mostly be attributed to the sn-1,2-
DAG isoforms (Rando and Young, 1984). The mechanism for
lipid-induced insulin resistance in liver is similar to what is
observed in skeletal muscle, where PKCq has been shown to
be the predominant novel PKC isoform activated during lipid-
induced muscle insulin resistance (Griffin et al., 1999; Yu et al.,
2002). The molecular mechanism of DAG activation of PKCε in
hepatic insulin resistance is summarized in Figure 1.
Further evidence supporting intrahepatic lipid as the mediator
of hepatic insulin resistance comes from studies in which rats
consuming a high-fat diet were treated with low doses of 2,4-
dinitrophenol (DNP) to promotemitochondrial energy uncoupling
(Samuel et al., 2004). This treatment protected rats from devel-
oping hepatic steatosis, PKCε activation, and hepatic insulin
resistance (Samuel et al., 2004).
The specific role of PKCε in causing hepatic insulin resistance
was directly examined using antisense oligonucleotides (ASO),
which act preferentially in the liver and adipose tissue (Crooke,
2004). Using a specific PKCε antisense oligonucleotide, Samuel
et al. were able to show that knocking down PKCε expression in
liver protected rats from lipid-induced hepatic insulin resistance
despite increases in hepatic lipid content (Samuel et al., 2007).
Furthermore, they found that activation of PKCε caused hepatic
insulin resistance by directly binding to and inhibiting insulin
receptor kinase activity (Samuel et al., 2007). These results
have recently been replicated in PKCε knockout mice, which
were protected from insulin resistance induced by high-fat
feeding (Frangioudakis et al., 2009). Confirmation of this key
interaction between DAG, activation of PKCε, and hepatic insulin
Figure 1. Molecular Mechanism of
Diacylglycerol-PKCε Mediated Hepatic
Insulin Resistance
The accumulation of diacylglycerol (DAG) in the
liver leads to the activation of protein kinase Cε
(PKCε), which subsequently inhibits the insulin
receptor kinase. This then leads to decreased
insulin-stimulated tyrosine phosphorylation (pY)
of insulin receptor substrate-1 and -2 (IRS-1,
IRS-2), resulting in reduced insulin activation of
1-phosphoinositol 3-kinase (PI 3-kinase) and
Akt2. Reduced Akt2 activation results in de-
creased glycogen synthase (GS)-mediated gly-
cogen synthesis and decreased suppression of
gluconeogenesis, which in turn leads to glucose
release through glucose transporter 2 (GLUT2).
FATP5, fatty acid transport protein 5; FOXO,
forkhead box protein O; G6Pase, glucose-6-
phosphatase; GSK3, glycogen synthase kinase-
3; LCoAs, long-chain fatty acids; PDK, pyruvate
dehydrogenase kinase; PEPCK, phosphoenol-
pyruvate carboxykinase; PIP2, phosphatidylino-
sitol bisphosphate; PIP3, phosphatidylinositol
trisphosphate; PH, pleckstrin homology domain;
PTB, phosphotyrosine binding domain; SH2, src
homology domain.
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models of NAFLD-associated hepatic insulin resistance (Birken-
feld et al., 2011a; Choi et al., 2007b; Erion et al., 2009; Jornayvaz
et al., 2010a, 2010b, 2011, 2012; Lee et al., 2011; Nagai et al.,
2009; Neschen et al., 2005; Savage et al., 2006; Zhang et al.,
2007).
Mechanisms of Increased Hepatic Diacylglycerol
Content
There are multiple causes for net accumulation of DAGs in the
liver and PKCε activation resulting in hepatic insulin resistance
(Figure 2). First, DAGs can accumulate following an increased
delivery of chylomicron remnants to the liver. Second, hepatic
accumulation of DAGs can result from increased fatty acid
release from adipocytes. Third, postprandial hyperinsulinemia
due to skeletal muscle insulin resistance can result in increased
hepatic de novo lipogenesis, leading to an increase in hepatic
DAG content. Finally, decreased mitochondrial function can
also result in the net accumulation of hepatic DAG content.
Caloric intake and diet composition. Themost prevalent cause
of NAFLD in Western society can be attributed to energy imbal-
ance, where caloric intake exceeds caloric expenditure, leading
to an increase in the rate of substrate delivery to the liver, which
exceeds the rate of hepatic fatty acid oxidation and the conver-
sion of DAGs to neutral lipids (triacylglycerols [TAGs]) and export
as VLDL (Shulman, 2000). Mice fed a high-fat ketogenic diet
develop severe hepatic steatosis and profound hepatic insulin
resistance despite manifesting increased energy expenditure
and weight loss (Jornayvaz et al., 2010a). In this case, hepatic
DAG content was increased by 350% and resulted in PKCε
activation, decreased insulin-stimulated IRS2 tyrosine phos-
phorylation, and decreased suppression of hepatic glucose
production during a hyperinsulinemic-euglycemic clamp.
Decreased mitochondrial function. As noted, hepatocellular
DAG content reflects a balance between rates of lipogenesis,rates of mitochondrial fatty acid oxidation, and conversion of
DAGs to TAGs. It is therefore possible that decreased
rates of mitochondrial oxidation relative to rates of hepatic
lipogenesis by the liver can also be a predisposing condition to
net DAG accumulation and hepatic insulin resistance. This
mechanism has been well documented in the muscle of healthy,
lean, insulin-resistant, elderly individuals (Petersen et al., 2003)
and in the muscle of young, lean, insulin-resistant offspring
of parents with type 2 diabetes (IR offspring) (Befroy et al.,
2007; Morino et al., 2005; Petersen et al., 2004), in which
increased intramyocellular lipid content was associated with
decreased basal rates of tricarboxylic acid flux (VTCA) and
decreased basal rates of adenosine triphosphate (VATP) syn-
thesis, as assessed by 13C/31P magnetic resonance spectros-
copy (MRS), respectively. This reflects an imbalance between
rates of fatty acid delivery/uptake into the muscle cell relative
to rates of intramyocellular lipid utilization. In the latter situation,
this reduction in VTCA flux and VATP synthesis could be attributed
to a reduction in the ratio of slow-twitch to fast-twitch muscle
fiber types and a reduction in mitochondrial content, as as-
sessed by electron microscopy (Morino et al., 2005; Petersen
et al., 2004). It is important to note that these observed reduc-
tions in mitochondrial function in both the elderly and young
lean insulin-resistant offspring occur independently of reduc-
tions in muscle ATP content and, therefore, must reflect reduced
energy requirements of the muscle cell, possibly due to reduc-
tions in the ratio of type 1 to type 2 muscle fiber types, as was
observed in the IR offspring, and/or some other unknown
factors.
It is also important to emphasize that increases in intramyocel-
lular lipid reflect an imbalance between fatty acid uptake by
the cell and intracellular lipid metabolism. This can occur in the
presence of low, normal, or even increased rates of mitochon-
drial oxidation/phosphorylation activity. The best example of
this is seen in muscle-specific PGC-1a overexpressing mice,Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 575
Figure 2. Mechanisms of Hepatocellular
Diacylglycerol Accumulation
Increases in hepatic diacylglycerol (DAG) content
result from an imbalance in the rate of fatty acid
delivery/uptake relative to rates of mitochondrial
fatty acid oxidation and conversion of DAGs to
triglycerides (TAGs). Increased energy intake
exceeding rates of energy expenditure is the most
common cause of NAFLD and DAG-PKCε-
induced hepatic insulin resistance, which is most
often seen in exogenous obesity. Predisposing
genetic factors, such as ApoC3 gene variants re-
sulting in increased plasma ApoC3 concentra-
tions, result in suppression of lipoprotein lipase
activity, increased postprandial chylomicron
remnants and increased hepatic fat uptake,
increased hepatic DAG content, and PKCε-
mediated hepatic insulin resistance. Defects in
adipocyte fat storage, as seen in lipodystrophy or
due to genetic alterations (e.g., mutations in
PPARg or perilipin (Agostini et al., 2006; Gandotra
et al., 2011), also can result in increased fat
delivery to the liver, NAFLD, and hepatic insulin
resistance. Genetic or acquired defects in
mitochondrial fatty acid oxidation may also
predispose to NAFLD and DAG-PKCε-mediated
hepatic insulin resistance. Finally, fatty acids
released from adipocytes can enter the liver
through the liver specific fatty acid transport
protein 5 (FATP5), resulting in increased long-
chain fatty acids (LCoAs) (Schaffer and Lodish,
1994), which can then be converted to DAG.
Cell Metabolism
Perspectivewhich have increased muscle mitochondrial content and
increased rates of basal mitochondrial VATP synthesis but are
prone to muscle lipid and DAG accumulation associated with
PKCq activation and muscle insulin resistance when fed
a high-fat diet (Choi et al., 2008). Increases in muscle DAG
content in these mice can be attributed to increased CD36
expression in skeletal muscle, leading to a situation where fatty
acid uptake by the muscle cell exceeds rates of intramyocellular
lipid utilization, resulting in net increases in muscle DAG content
despite increased basal rates of mitochondrial function.
Although reduced mitochondrial activity associated with muscle
insulin resistance is clearly an acquired event associated with
aging (Petersen et al., 2003) that can be prevented by targeted
overexpression of catalase to the mitochondria (Lee et al.,
2010), it remains to be determined whether decreased mito-
chondrial function is a primary or a secondary event in the devel-
opment of increased intramyocellular lipid uptake and muscle
insulin resistance in young, lean IR offspring (Befroy et al.,
2007; Morino et al., 2005; Petersen et al., 2004). In this regard,
a recent study by Morino et al. has found reduced LPL expres-
sion leading to decreased activity of peroxisome proliferator-
activated receptor (PPAR) d in skeletal muscle of young, lean
insulin-resistant subjects, suggesting that reductions in mito-
chondrial function and content may be an acquired event in
these individuals that is due to reduced LPL expression in
skeletal muscle (Morino et al., 2012). Nevertheless, given the
potentially important role that intracellular lipids have in medi-
ating muscle insulin resistance, any decrease in mitochondrial
function would be expected to exacerbate lipid-induced muscle
insulin resistance.
Genetic evidence demonstrating that reductions in liver
mitochondrial function can be a predisposing factor to NAFLD
and hepatic insulin resistance is observed in long-chain576 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.acyl-CoA dehydrogenase (LCAD) knockout mice, which have
reduced rates of hepatic mitochondrial fatty acid oxidation and
are prone to develop hepatic steatosis associated with
increased hepatic DAG content, PKCε activation, and hepatic
insulin resistance when fed a high-fat diet (Zhang et al., 2007).
Whether similar reductions in hepatic mitochondrial oxidation
is associated with NAFLD in humans is less clear, with some
studies demonstrating reduced (Cortez-Pinto et al., 1999;
Schmid et al., 2011) and other studies suggesting increased
rates of liver mitochondrial metabolism (Sunny et al., 2011).
The role of muscle insulin resistance in promoting hepatic
steatosis. Selective insulin resistance in skeletal muscle can
lead to a redistribution of substrates away from muscle to the
liver, resulting in hepatic steatosis. An example of this occurs
in muscle-specific, insulin receptor knockout (MIRKO) mice
(Kim et al., 2000b). In these mice, insulin-stimulated muscle
glucose transport and glycogen synthesis were decreased by
80%, whereas insulin-stimulated glucose transport in adipo-
cytes was increased 3-fold, demonstrating that selective insulin
resistance in muscle promotes redistribution of substrates
toward increased adiposity (Kim et al., 2000b). These results
were confirmed in mice lacking muscle glucose transporter
4 (GLUT4), which had a 90% decrease in insulin-stimulated
muscle glucose uptake (Kim et al., 2001b) and a redistribution
of substrates to the liver, making them prone to develop hepatic
steatosis (Kotani et al., 2004). Petersen et al. translated these
findings to humans by demonstrating that selective insulin
resistance in skeletal muscle, which is observed in young,
lean, healthy individuals in the bottom quartile of whole-body
insulin sensitivity, diverts the energy of ingested carbohydrates
away from muscle glycogen synthesis and toward hepatic de
novo lipogenesis, thus predisposing these individuals to in-
creased plasma triglycerides, reduced plasma high-density
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visceral fat mass measured with abdominal MRI was similar
between insulin-resistant and insulin-sensitive subjects, sug-
gesting that these features of the metabolic syndrome can
develop independently of increased visceral adiposity. More-
over, no differences in plasma adipokines (adiponectin, IL-6,
resistin, RBP-4, and TNFa) concentrations were observed
between the insulin-resistant and insulin-sensitive individuals,
suggesting that these circulating adipocytokines were not
responsible for causing insulin resistance in these individuals
(Petersen et al., 2007). Consistent with these results, Stefan
et al. reported that in a cohort of obese people, insulin-sensitive
and insulin-resistant individuals were distinguished on the basis
of lipid accumulation in the muscle and liver, but not according
to visceral or subcutaneous adiposity (Stefan et al., 2008). This
study was further supported by the finding that intrahepatic
triglyceride content, but not visceral adiposity, was associated
with insulin resistance and increased secretion of triglycerides
(Fabbrini et al., 2009). To directly examine the hypothesis that
muscle insulin resistance can lead to a redistribution of sub-
strates to the liver, resulting in increased hepatic de novo lipo-
genesis, Rabøl et al. assessed the effect of a single bout of
exercise on hepatic de novo lipogenesis and hepatic triglyc-
eride synthesis after the ingestion of a carbohydrate-rich meal
in healthy, young, lean, insulin-resistant individuals (Rabøl
et al., 2011). The rationale for this study came from a previous
study by Perseghin et al., who found that a single 45 min bout
of exercise reversed defects in insulin-stimulated glucose
transport/phosphorylation activity and muscle glycogen syn-
thesis in young lean insulin-resistant offspring of parents with
type 2 diabetes (Perseghin et al., 1996). Rabøl et al. showed
that a single bout of exercise resulted in a 30% decrease in
hepatic de novo lipogenesis and a 40% reduction in net hepatic
triglyceride synthesis, without any changes in fasting or post-
prandial plasma glucose and insulin concentrations, demon-
strating that skeletal muscle insulin resistance is an early
therapeutic target for the prevention and treatment of athero-
genic dyslipidemia and NAFLD in young insulin-resistant indi-
viduals prone to develop the metabolic syndrome (Rabøl
et al., 2011).
Taken together, these studies in mice and humans support
the concept that selective muscle insulin resistance is an impor-
tant and early factor in the pathogenesis of atherogenic dyslipi-
demia and NAFLD in patients prone to develop the metabolic
syndrome and type 2 diabetes.
Lipodystrophy. Assessing the specific role of NAFLD in the
development of hepatic insulin resistance is challenging
because it is usually associated with obesity, so the changes in
liver insulin action due to steatosis and those attributable to
increased adiposity are difficult to ascertain (Gastaldelli et al.,
2004; Miyazaki et al., 2002a). The lipodystrophies offer a unique
possibility to assess the role of hepatic lipid accumulation in this
process without any peripheral or visceral fat expansion. These
conditions may be congenital or acquired. They are character-
ized by partial or complete loss of adipose tissue and associated
with low plasma leptin concentrations and hyperphagia. The lack
of subcutaneous fat causes hypertriglyceridemia, insulin resis-
tance, and ectopic fat deposition, which include the develop-
ment of substantial hepatic steatosis.Mice expressing the dominant-negative protein A-ZIP/F-1 are
virtually devoid of white adipose tissue (fatless mice) and
develop fat accumulation in the liver and skeletal muscle, leading
to profound hepatic and peripheral insulin resistance (Kim et al.,
2000a). Interestingly, transplantation of wild-type fat in these
mice reversed the hyperglycemia, lowered plasma insulin levels,
decreased ectopic fat content in liver and muscle, and improved
liver andmuscle insulin sensitivity (Kim et al., 2000a). Most of the
metabolic defects associated with lipodystrophy in mice were
also corrected by the administration of leptin (Shimomura
et al., 1999).
Consistent with these mice studies, lipodystrophic patients
benefit from exogenous administration of recombinant leptin
(Oral et al., 2002). A study by Petersen et al. provided important
mechanistic insights into how leptin therapy was working in
these patients by demonstrating that before leptin replacement,
lipodystrophic patients had higher basal rates of glucose
production than the control subjects matched for age, weight,
and sex (Petersen et al., 2002). Moreover, these patients had
severe liver and muscle insulin resistance, as reflected by
the lack of suppression of hepatic glucose production and
decreased stimulation of peripheral glucose uptake during a
hyperinsulinemic-euglycemic clamp, which was associated
with severe hepatic steatosis. However, after leptin replacement,
there was a marked reduction in both liver and intramyocellular
lipid content, which mostly could be attributed to reduction in
caloric intake, with concomitant improvement in both hepatic
and peripheral insulin sensitivity (Petersen et al., 2002). Taken
together, these studies in lipodystrophic patients and mouse
models of lipoatrophy demonstrate that ectopic lipid accumula-
tion in liver can lead to hepatic insulin resistance even in the
absence of peripheral and visceral adiposity and that reversal
of hepatic steatosis leads to reversal of hepatic insulin resis-
tance.
Predisposing genetic factors for NAFLD. Importantly, there
are ethnic differences in the prevalence of NAFLD. Notably,
males of Asian-Indian ancestry have a higher risk of developing
NAFLD, which is associated with marked hepatic insulin resis-
tance (Petersen et al., 2006), despite having a normal body
mass index (BMI) (<25 kg/m2). In this case, the average liver
triglyceride content almost doubled in the lean Asian-Indian
men compared with age-weight-BMI-matched Caucasian
men. Increased liver fat content in young, normal weight Asian-
Indian men put them at increased risk of developing type 2
diabetes, NAFLD, and liver cirrhosis (Petersen et al., 2006).
Recently, Petersen et al. showed that common gene variants
(e.g., C-482T/T-455C) in the insulin response element of the
apolipoprotein C3 (ApoC3) gene are at higher risk of developing
NAFLD and insulin resistance (Petersen et al., 2010). The carriers
of these polymorphisms have approximately 30% higher
plasma concentrations of ApoC3, as well as postprandial hyper-
triglyceridemia, compared to individuals who are wild-type
homozygotes for ApoC3 (C-482/T-455). ApoC3 inhibits lipopro-
tein lipase activity; consequently, these carriers have decreased
triglyceride clearance following an intravenous infusion of lipids
and increased postprandial hypertriglyceridemia and chylomi-
crons remnants, leading to NAFLD and hepatic insulin resistance
(Petersen et al., 2010). Furthermore, modest weight reduction in
these subjects reversed hepatic steatosis and insulin resistanceCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 577
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gene variants, which result in a 30% increase in plasma ApoC3
concentrations, do not directly cause hepatic steatosis but
represent a predisposing condition for individuals who carry
them. Therefore, when exposed to a toxic environment (i.e.,
increased fat and calorie dense foods), individuals with ApoC3
gene variants (C-482T/T-455C) are more susceptible to develop
NAFLD and hepatic insulin resistance. Furthermore, because
this is a predisposing gene-environment interaction, this associ-
ation between increased ApoC3 concentrations and increased
prevalence of hepatic steatosis will typically be observed only
in lean individuals who normally have a low prevalence of
NAFLD, in contrast to overweight/obese individuals where
some degree of hepatic steatosis is almost universally present.
In support of this hypothesis, it has been shown recently that
mice with hepatic overexpression of ApoC3 had no metabolic
phenotype (e.g., no hepatic steatosis or insulin resistance)
when fed a regular chow diet but developed severe hepatic
steatosis associated with increased hepatic DAG content,
PKCε activation, and hepatic insulin resistance when placed
on a high-fat diet (Lee et al., 2011).
Another group at risk of developing NAFLD and hepatic insulin
resistance are Hispanics adults and children (Liska et al., 2007).
In this population, genetic screening identified an allele
(Met148Ile) of the enzyme patatin-like phospholipase domain-
containing protein 3, which is encoded by the PNPLA3 gene,
to be strongly correlated with the development of NAFLD
(Romeo et al., 2008). However, in contrast to the ApoC3 gene
variants (T482/C455) described above, this PNPLA3 gene
variant was not associated with insulin resistance, suggesting
that NAFLD can be dissociated from hepatic insulin resistance
(Kantartzis et al., 2009). Whether hepatic DAG content in
these individuals increases along with hepatic TAG content is
unknown. However, it should be noted that in all studies to
date that have examined the relationship between NAFLD in
these PNPLA3 gene variants with NAFLD have used obese
individuals as control subjects, who almost certainly have
some degree of hepatic steatosis associated with hepatic
insulin resistance making it difficult to discern whether or not
PNPLA3 gene variants with NAFLD truly manifest hepatic insulin
resistance. Therefore, it will be very important to examine
hepatic insulin sensitivity in lean PNPLA3 variants with NAFLD
compared to lean healthy control subjects without NAFLD to
get a definitive answer to this question.
Controversies and Alternative Hypotheses
NAFLD is strongly associated with hepatic insulin resistance
and type 2 diabetes. However, some studies have reported a
dissociation between NAFLD and hepatic insulin resistance.
Among these, Monetti et al. reported that mice overexpressing
acylCoA:diacylglycerol acyltransferase 2 (DGAT2), the enzyme
that catalyzes the conversion from DAG to TAG (Figure 3), in
the liver have normal hepatic insulin sensitivity despite increased
hepatic TAG, DAG, and ceramide content (Monetti et al., 2007).
In this study, insulin sensitivity was assessed using intraper-
itoneal glucose tolerance tests and the hyperinsulinemic-
euglycemic clamp technique (Monetti et al., 2007). Due to high
hepatic DAG content in these DGAT2 transgenic mice and
previous studies demonstrating a key role of DAG-PKCε activa-578 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.tion in mediating hepatic insulin resistance, these results were
surprising to us. Given this apparent paradox, we decided to
reconsider the role of DAG in causing hepatic insulin resistance
in this mouse model of severe hepatic steatosis. Therefore, we
performed detailed studies to evaluate insulin sensitivity in
awake mice by using the hyperinsulinemic-euglycemic clamp
technique combined with radiolabeled glucose to assess rates
of whole-body glucose turnover. We also assessed signaling
events typically associated with an increase in hepatic DAG
content (i.e., PKCε activation, as well as potential alterations in
insulin signaling downstream of the insulin receptor kinase).
Consistent with the observations of Monetti et al., we found
that DGAT2 transgenic mice had an increase in hepatic TAG,
DAG and ceramide content (Jornayvaz et al., 2011). However,
in contrast to the findings of Monetti et al. (Monetti et al.,
2007), we found that the DGAT2 transgenic mice had severe liver
insulin resistance, as reflected by the lack of suppression of
hepatic glucose production during a hyperinsulinemic-euglyce-
mic clamp. We also found that the increase in hepatic DAG
content led to PKCε activation, resulting in decreased insulin-
stimulated IRS2 tyrosine phosphorylation and Akt phosphoryla-
tion. Although the slight (8%) increase in ceramides may also
have contributed to hepatic insulin resistance, it is likely that
hepatic DAG accumulation was the major factor responsible
for the development of hepatic insulin resistance in these mice,
given the much larger increases in hepatic DAG content
compared to relatively small increases in hepatic ceramide
content observed in these mice (Jornayvaz et al., 2011).
Although the main conclusion of these studies differs from that
obtained by Monetti et al. (Monetti et al., 2007), several aspects
of both studies were similar. We used the same strain of mice
with the same housing and breeding conditions. The critical
difference in our studies was the assessment of hepatic insulin
response. The hyperinsulinemic-euglycemic clamp is the gold
standard for directly quantifying hepatic insulin sensitivity,
whereas glucose tolerance reflects the coordinated response
to a glucose load; without measurements of plasma insulin
concentrations (Monetti et al., 2007), insulin sensitivity cannot
be assessed (Ayala et al., 2010). It is likely that differences
in clamp procedures are responsible for the critical differences
between our studies. Monetti et al. performed clamp studies
only 3 days following catheter implantation. However, 5 to
7 days are required for mice to fully recover from the stress
of surgery and return to their presurgical body weight
(Ayala et al., 2010). Consistent with this hypothesis, Monetti
et al. observed high rates of hepatic glucose production
during the hyperinsulinemic-euglycemic clamp (approximately
20 mg/[kg-min]) in both DGAT2 transgenic and control wild-
type mice. Without a positive control group showing normal
suppression of hepatic glucose production during the hyperinsu-
linemic-euglycemic clamp, it is not possible to discern hepatic
insulin response in the DGAT2 transgenic group. Moreover,
without reporting basal rates of hepatic glucose production prior
to the insulin infusion, it is not possible to calculate the suppres-
sion in hepatic glucose production during the hyperinsulinemic-
euglycemic clamp. Thus, while wild-type and DGAT2 transgenic
mice had similar rates of hepatic glucose production during the
hyperinsulinemic-euglycemic clamps done by Monetti et al.,
both their wild-type control mice and their DGAT2 transgenic
Figure 3. Metabolic Pathways Leading to Hepatic Diacylglycerol Accumulation
The glycerol 3-phosphate (or phosphatidic acid) pathway represents the de novo lipogenesis route in the synthesis of triglycerides (TAG) and phospholipids.
Acyl-CoA:glycerol-sn-3-phosphate acyltransferase (GPAT) catalyzes the acylation of sn-glycerol-3-phosphate with acyl-coenzyme A (acyl-CoA) to generate
lysophosphatidic acid (LPA). LPA is thought to be the rate-controlling step in TAG synthesis. Subsequently, the enzymes acyl-CoA:1-acylglycerol-sn-3-
phosphate acyltransferase (AGPAT), phosphatidic acid phosphatase (PAP), and diacylglycerol:acyl-CoA acyltransferase (DGAT) generate phosphatidic acid
(PA), diacylglycerol (DAG), and TAG. In the liver, TAG is either deposited in intracellular vacuoles or exported in very low-density lipoproteins (VLDL) particles. LPA
and PA require translocation through the cytosol for TAG synthesis at the endoplasmic reticulum if they are not synthesized in the endoplasmic reticulum. DAG
can be hydrolyzed to monoacylglycerol (MAG) by hormone-sensitive lipase (HSL) and subsequently to glycerol by monoglyceride lipase (MGL). These reactions
release fatty acids. Glycerol can be used as a substrate for gluconeogenesis. The conversion from TAG to DAG is mediated by adipose triglyceride lipase (ATGL).
Comparative gene identification-58 (CGI-58) is an activator of ATGL. DAG activates PKCε membrane translocation to inhibit the insulin receptor kinase.
PhospholipaseC can release DAG frommembrane lipids. Whether DAGderived from the phospholipase C pathway and lipid droplets can lead to PKCε activation
and hepatic insulin resistance remains to be determined.
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et al., 2007). In conclusion, increased hepatic DGAT2 expression
increases hepatic DAG content and confirms the link between
hepatic DAG, PKCε activation, and hepatic insulin resistance
(Jornayvaz et al., 2011). Moreover, the demonstration of insulin
resistance in these mice strengthens the link between hepatic
steatosis and hepatic insulin resistance and supports the
hypothesis that DAG-induced PKCε activation plays a major
role in NAFLD-associated hepatic insulin resistance.
Importantly, in this study (Jornayvaz et al., 2011) hepatic
insulin resistance was not associated with endoplasmic retic-
ulum (ER) stress or inflammation, which are alternative views
to explain insulin resistance in obesity and type 2 diabetes
(Hotamisligil, 2006, 2008; Lazar, 2005; Ozcan et al., 2004;
Taubes, 2009). Obesity combines insulin resistance and a
proinflammatory state, andmechanistically inflammatory signalsare known to affect insulin action (Shoelson et al., 2006). Specif-
ically, inflammatory signals, such as IL-6 or TNFa, activate
kinases, such as c-jun-N-terminal kinase (JNK) and Ik kinase b,
which are known to increase IRS1 serine phosphorylation on
critical sites that block insulin-stimulated IRS1 tyrosine phos-
phorylation (Boden et al., 2005). ER stress might also activate
inflammatory pathways to protect cells from producing aberrant
proteins, often referred to as the unfolded protein response
(Hotamisligil, 2005). This activation has been shown to occur in
human obesity (Boden et al., 2008) and also in rodent models
of obesity (Ozcan et al., 2004), and modulation of ER stress
can ameliorate JNK activation and the development of insulin
resistance (Ozcan et al., 2006). However, recent studies in
X-box binding protein (XBP) knockout mice have disassociated
inositol requiring enzyme (IRE)-1a-mediated JNK-1 activation
from hepatic insulin resistance (Jurczak et al., 2012).Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 579
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Probably the most critical question regarding all of the proposed
cellular mechanisms of NAFLD-associated hepatic insulin resis-
tance is whether any of them will translate to explain hepatic
insulin resistance in humans with NAFLD (Hotamisligil, 2006,
2008; Lazar, 2005; Ozcan et al., 2004; Shulman, 2000; Taubes,
2009). Evidence in support of an important role for DAG-
mediated activation of PKCε in this process comes from a recent
study that found that hepatic DAG content in cytoplasmic lipid
droplets was the best predictor of insulin resistance in obese,
nondiabetic individuals with NAFLD and varying degrees of
insulin resistance (Kumashiro et al., 2011). Furthermore hepatic
DAG content and hepatic insulin resistance in these individuals
was strongly correlated with PKCε activation, similar to what
was observed in previous rodent studies (Samuel et al., 2004,
2007). In contrast, there was no significant association between
insulin resistance and plasma or hepaticmarkers of inflammation
or hepatic ceramide content. Moreover, ER stress markers were
only partly correlated with insulin resistance and there was no
relationship between the IRE-1a/JNK-1 ER stress pathway and
insulin resistance. These data suggest that the IRE-1a/JNK-1
ER stress pathway does not cause insulin resistance and is
consistent with recent studies that have dissociated hepatic
insulin resistance from activation of the IRE-1a/JNK-1 ER stress
pathway (Birkenfeld et al., 2011b; Jurczak et al., 2012). Taken
together, these studies show that hepatic DAG content associ-
ated with PKCε activation is the best predictor of insulin
resistance in humans, and support the hypothesis that NAFLD-
associated hepatic insulin resistance is caused by an increase
in hepatic DAG content, which results in activation of PKCε
and subsequent reductions in hepatic insulin signaling (Kuma-
shiro et al., 2011).
Diacylglycerol Compartmentation
Recent studies in both humans (Kumashiro et al., 2011) and
rodents (Birkenfeld et al., 2011b; Jornayvaz et al., 2011; Jurczak
et al., 2012) have clearly demonstrated that compartmentation
of DAGs within the hepatocyte is a major factor in determining
whether PKCε and hepatic insulin resistance occurs. Figure 3
summarizes the metabolic pathways leading to hepatic DAG
accumulation. DAG can result from the glycerol 3-phosphate
(or phosphatidic acid) pathway, which represents the lipogen-
esis route in the synthesis of TAG and phospholipids. Most
studies to date have clearly implicated DAGs derived from this
pathway in activation of PKCε and hepatic insulin resistance.
However intracellular DAGs can also be derived from TAG
hydrolysis of lipid droplets, mediated by adipose triglyceride
lipase (ATGL), and activation of phospholipase C, which will
release DAGs from membrane lipids. Whether DAGs derived
from these latter two pathways can lead to PKCε activation
and hepatic insulin resistance remains to be determined. Indeed,
compartmentation of DAG in a neutral compartment, where it
cannot activate PKCε, may explain why hepatic DAG content
may not always correlate with hepatic insulin resistance in
some mouse models. For example, mice treated with an ASO
targeting comparative gene identification-58 (CGI-58) develop
NAFLD associated with increased hepatic TAG, DAG, and ce-
ramide content but also show improved glucose tolerance
when assessed by an intraperitoneal glucose tolerance test580 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.(Brown et al., 2010). CGI-58 encodes a protein that acts as a co-
activator of ATGL (also known as desnutrin), which hydrolyzes
TAG to DAG (Figure 3). Interestingly, CGI-58 also possesses
similar properties as the enzyme acyl-CoA:1-acylglycerol-sn-3-
phosphate acyltransferase (AGPAT), which converts lysophos-
phatidic acid to phosphatidic acid and may, therefore, be
involved in neutral lipids and DAG synthesis (Montero-Moran
et al., 2010). Although these results dissociate hepatic DAG
content and hepatic insulin resistance, more careful studies
are required. First, the effect of CGI-58 ASO on hepatic insulin
sensitivity in mice needs to be assessed directly, using hyperin-
sulinemic-euglycemic clamp studies because intraperitoneal
glucose tolerance tests do not directly examine hepatic insulin
sensitivity, and studies in conditions not matched for body
weight may result in misleading conclusions (Ayala et al., 2010).
Furthermore, it will be important to understand where DAGs
localize within the hepatocyte in this model, as reflected by
recent studies demonstrating that DAGs in the cytosolic com-
partment of the hepatocyte best correlated with PKCε activation
and insulin resistance in contrast to DAGs in other cellular
compartments (Jornayvaz et al., 2011; Kumashiro et al., 2011).
Clearly, further studies are required to describe how and where
DAGs accumulate within the hepatocyte and lead to PKCε acti-
vation and hepatic insulin resistance. Moreover, it will be impor-
tant to examine whether certain subspecies of DAGs are more
potent at activating PKCε and causing hepatic insulin resistance.
Therapeutic Implications
Reduction in hepatic steatosis reduces hepatic insulin resis-
tance. If hepatic lipid is an important mediator of hepatic insulin
resistance, it would be expected that reduction of hepatic
steatosis in patients with NAFLD and type 2 diabetes would
reduce hepatic insulin resistance. To test this hypothesis, Pe-
tersen et al. subjected patients with NAFLD and type 2 diabetes
to a hypocaloric diet (1,200 kcal/d) for approximately 2 months,
during which time these individuals lost, on average, 8kg of
body weight (Petersen et al., 2005). Following weight stabiliza-
tion, this modest weight loss was associated with an 80%
reduction in hepatic TAG content, as assessed by 1H MRS,
and normalization of fasting plasma glucose concentrations,
rates of basal hepatic glucose production, and hepatic sensi-
tivity, as reflected by normal suppression of hepatic glucose
production during a hyperinsulinemic-euglycemic clamp (Pe-
tersen et al., 2005). Although hepatic DAG content was not
assessed in this study, Kumashiro and coworkers have recently
demonstrated a very strong relationship (R = 0.90, p < 0.001)
between hepatic TAG content and hepatic DAG content
measured in human liver biopsy studies (Kumashiro et al.,
2011). Furthermore this normalization in hepatic insulin sensi-
tivity occurred independently of any changes in circulating
inflammatory adipocytokines (Petersen et al., 2005). These
results have since been replicated in a recent study by Lim
et al., who found that energy restriction (600 kcal/day) for 8weeks
resulted in modest weight loss, reduced hepatic TAG content,
and normalization of hepatic insulin sensitivity in patients with
NAFLD and type 2 diabetes (Lim et al., 2011).
Among currently available antidiabetic drugs, thiazolidine-
diones, which are potent peroxisome proliferator-activated
g (PPARg) agonists, can also reduce hepatic steatosis.
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40% after 3 months of treatment in patients with NAFLD and
type 2 diabetes (Mayerson et al., 2002). This effect was accom-
panied by a reduction (40%) in intramyocellular TAG content
and improved suppression of adipocyte lipolysis during a hyper-
insulinemic-euglycemic clamp (Mayerson et al., 2002). Subse-
quent studies have confirmed that rosiglitazone treatment can
decrease hepatic fat content in patients with NAFLD and type
2 diabetes and improve hepatic insulin sensitivity (Tiikkainen
et al., 2004). Similar reductions in hepatic steatosis were also
reported for pioglitazone treatment in patients with NAFLD and
type 2 diabetes (Miyazaki et al., 2002b). Taken together, these
data support the hypothesis that thiazolidinedione-associated
improvement in insulin sensitivity is mediated mostly by shifting
intracellular lipids from ectopic sites in liver and muscle into
adipose tissue, as this is the main site of expression of PPARg
(Kim et al., 2003; Shulman, 2000).
Promoting hepatic mitochondrial uncoupling and hepatic
energy dissipation. As discussed earlier, promoting hepatic
mitochondrial uncoupling by treating rats with low-dose 2,4-
dinitrophenol, a potent mitochondrial uncoupler, decreased
hepatic TAG content and protected rats from lipid-induced
hepatic insulin resistance (Samuel et al., 2004). Similar observa-
tions have been made in skeletal muscle in transgenic mice with
muscle-specific overexpression of uncoupling protein 3 (UCP3)
(Choi et al., 2007a). These results demonstrate that increasing
mitochondrial energy uncoupling promotes mitochondrial
substrate oxidation, leading to reductions in tissue TAG/DAG
content, decreased nPKC activation, and prevention of insulin
resistance in both liver and skeletal muscle. Besides providing
important evidence in support of the DAG-PKCε hypothesis
of hepatic insulin resistance, these results also provide a
pharmacologic approach to the treatment of NAFLD-associated
hepatic insulin resistance. Consistent with these findings,
Savage et al. have shown that promoting hepatic fatty acid
oxidation and inhibiting fatty acid synthesis by knocking down
hepatic expression of acetyl-CoA carboxylase 1 and 2 (ACC1
and ACC2, respectively) using antisense oligonucleotides
prevented hepatic steatosis, hepatic DAG accumulation, PKCε
activation, and hepatic insulin resistance in high-fat fed rats
(Savage et al., 2006). However, it is important to note that
simply promoting mitochondrial fat oxidation at the expense of
decreased glucose oxidation is not likely to solve the problem
of NAFLD and hepatic insulin resistance unless one can promote
mitochondrial energy uncoupling and dissipate the excess
stored energy in the liver as DAGs and TAGs. Along with these
lines, Birkenfeld et al. have recently shown that mice lacking
the ‘‘I am not dead yet’’ (INDY) gene (mINDY/) were protected
from high-fat diet-induced obesity and insulin resistance
(Birkenfeld et al., 2011a). The rationale for this study in mice
came from previous experiments in D. melanogaster and its
homolog in C. elegans with reduced expression of the INDY
gene that demonstrated increased longevity in a manner akin to
caloric restriction. The liver of mINDY/ mice had a reduced
ATP/ADP ratio, which subsequently led to activation of AMP-
activated protein kinase (AMPK) and peroxisome proliferator-
activated receptor-g coactivator-1a (PGC-1a), and inhibition
of ACC2 and sterol regulatory element-binding protein 1c
(SREBP1c) protein levels. Therefore, mINDY/ mice hadimproved mitochondrial biogenesis and increased hepatic lipid
oxidation, with a subsequent reduction in hepatic TAG and
DAG content. Consistent with the DAG-PKCε hypothesis,
mINDY/ mice were protected from high-fat diet-induced
hepatic insulin resistance and displayed decreased PKCε
activation. Importantly, mINDY/ mice had no difference in
hepatic ceramide content compared to their wild-type littermate
controls, excluding this lipid intermediate from involvement in
hepatic insulin resistance in this mouse model (Birkenfeld
et al., 2011a). Moreover, gene set enrichment analysis revealed
markedly increased expression of pathways regulating mito-
chondrial genes and mitochondrial density assessed by electron
microscopy in mINDY/ mice.
Conclusions and Future Perspectives
In conclusion, there is increasing evidence, not only in animal
models of NAFLD but also, more importantly, in humans
with NAFLD-associated with obesity, type 2 diabetes, and lipo-
dystrophy, that hepatic steatosis is strongly linked with the
development of hepatic insulin resistance. Moreover, these
studies support the hypothesis that DAG-induced PKCε activa-
tion, resulting in inhibition of insulin-stimulated insulin receptor
kinase activity, represents the root cause of hepatic insulin resis-
tance in all of these conditions. Reducing hepatic DAG content
by decreasing caloric intake and/or by increasing energy ex-
penditure through exercise clearly represents the healthiest
approach to treating NAFLD in these conditions. Based on
animal studies, novel therapies aimed at promoting hepatic
mitochondrial energy uncoupling should also prove to be an
effective treatment in lowering hepatic DAG content and
reversing hepatic insulin resistance. Further studies aimed at
understanding the potential role of DAG compartmentation in
activation of PKCε may also lead to new therapeutic targets.
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